• Report store
  • Atopic Dermatitis Market Insight, Epidemiology and Market Forecast -2030
Atopic Dermatitis Market
Atopic Dermatitis Market
Atopic Dermatitis Market Insight, Epidemiology and Market Forecast -2030

  • Published Date : Oct 2021

  • Pages : 263

  • Delivery Time : 24 Hours

  • Region : United States, EU5, Japan

Atopic Dermatitis Ad Market

DelveInsight’s ‘Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Atopic Dermatitis (AD), historical and forecasted epidemiology as well as the Atopic Dermatitis (AD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Atopic Dermatitis (AD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Atopic Dermatitis (AD) market size from 2018 to 2030. The report also covers current Atopic Dermatitis (AD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, Spain, Italy, France, and United Kingdom)
  • Japan

Study Period: 2018–2030

Atopic Dermatitis (AD) Disease Understanding and Treatment Algorithm

Atopic Dermatitis (AD) Overview

Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances.

AD presents different symptoms depending on the age of the person. Itching is the hallmark of AD; more than 85% of people with the condition experience this distressing symptom every day. The exact cause of AD is unknown. The basic understanding of AD is that inflammation results from compromised skin barrier leading to drier skin that is more prone to water loss and the entry of irritants. Thus, AD is caused by a complex interaction of immune dysregulation, epidermal gene mutations, and environmental factors that disrupt the epidermis causing intensely pruritic skin lesions.

There is currently no reliable biomarker that can distinguish the disease from other entities. However, the most commonly used biomarker is elevated total and/or allergen-specific serum IgE. Occasionally, patients carrying an AD diagnosis may display atypical clinical features, chronic dermatoses, infectious processes, and primary immunodeficiency may mimic the presentation leading to the differential diagnosis. Noninfectious dermatoses include contact dermatitis, seborrheic dermatitis, and psoriasis.

Atopic Dermatitis (AD) Diagnosis

At present, there is no specific test for AD, and no single symptom or feature can be used to identify the disease. Each patient has a unique combination of symptoms and rash appearance. Diagnosis of AD is based on the history and physical examination of the patient. In uncertain cases, a skin biopsy may be taken for a histopathological diagnosis of dermatitis.

Atopic Dermatitis (AD) Treatment

Significant psychological, social, and emotional impact is experienced by people with the condition daily. In addition to the visual and physical issues, AD can have a significant impact on the quality of life (QoL) of people. Currently, there is no cure for AD; however, it can be effectively managed with current treatment options. The pattern of the disease and its severity determine the kind of treatment the patient ought to receive.

The current US market for AD are dominated by topical treatment options such as emollients, topical corticosteroids (TCS) + antibiotics, topical calcineurin inhibitors (TCIs), and systemic treatment such as immunosuppressant, corticosteroids, Dupixent (Dupilumab), and others (phototherapy). Drugs like Dupixent (dupilumab) Eucrisa (Crisaborole) 2% ointment are approved in the US for treatment of AD. The maintenance therapy for AD consists of the liberal use of emollients and daily bathing practice with soap-free cleansers. The use of TCS is the first-line treatment for AD flare-ups. Pimecrolimus and Tacrolimus are TCIs that can be used in conjunction with TCS. Ultraviolet phototherapy is a safe and effective treatment for moderate-to-severe AD when first-line treatments are not adequate. In addition to these, antistaphylococcal antibiotics are effective in treating secondary skin infections. Patients with severe sleep disturbance due to pruritus are offered a short-term, intermittent course of an oral sedating antihistamine such as diphenhydramine (Benadryl) or hydroxyzine; however, they are not routinely recommended because of lack of evidence that they reduce pruritus and the risk of development of contact dermatitis.

Atopic Dermatitis (AD) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Atopic Dermatitis, Diagnosed Prevalent Population of Atopic Dermatitis, Severity-specific Distribution of Atopic Dermatitis in Adults, Severity-specific Distribution of Atopic Dermatitis in Pediatric Population, Gender-specific Distribution of Atopic Dermatitis in Adults, and Chronic Pruritus Prevalence in Atopic Dermatitis in the adults in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan market from 2018 to 2030.

Key Findings

This section provides glimpse of the AD epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

  • The total diagnosed prevalent population of AD in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan was estimated to be 25,091,967 in 2020.
  • Epidemiology assessed for AD showed that the US, in 2020, accounted for approximately 32,197,083 prevalent cases of AD.
  • In the EU5 countries, the prevalent population of AD was maximum in UK with 7,195,160 cases, followed by the France with 6,585,281 cases in 2020. While, the least number of cases were in Spain, with 4,678,148 cases in 2020.
  • Japan accounted for 9,510,049 prevalent AD cases in 2020.
  • The number of chronic pruritus adult prevalent population of AD in the United States is estimated to be 13,643,033 in 2020.
  • The total diagnosed prevalent population of AD in the seven major markets was found to be 52,941,993 in 2020. In the case of AD patients in the United States, the diagnosed prevalent cases were estimated to be 24,039,022 in 2020.
  • As per the analysis, a higher percentage of mild AD was observed in the 7MM, followed by moderate AD and severe AD in 2020 in the case of both children and adults. In the US, mild AD accounted for the highest cases in 2020, followed by moderate AD with 9,631,982 and 4,638,631, respectively. In contrast, the lowest cases were found in severe AD, with 1,765,569 cases, in 2020.
  • Among the gender-specific prevalent contribution, females are affected more by AD than males. In 2020, there were 6,039,851 prevalent cases of AD in males and 10,010,776 prevalent cases in females in the US.

Country- Wise Atopic Dermatitis (AD) Epidemiology

The epidemiology segment also provides the Atopic Dermatitis (AD) epidemiology data and findings across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Atopic Dermatitis (AD) Drug Chapters

The drug chapter segment of the Atopic Dermatitis (AD) report encloses the detailed analysis of Atopic Dermatitis (AD) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Atopic Dermatitis (AD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Atopic Dermatitis (AD) Marketed Drugs

Eucrisa/Staquis (Crisaborole): Pfizer

Eucrisa (crisaborole) is a non-steroidal phosphodiesterase-4 (PDE4) inhibitor indicated for the topical treatment of mild-to-moderate AD in patients 2 years of age and older. It is currently available as a 2% ointment. The drug is a small, boron-based molecule with low molecular weight, which allows easier penetration into the skin. It is important to note that the drug is approved under the name, Staquis, in Europe to treat adults and children from 2 years of age with mild-to-moderate AD and is used when dermatitis affects up to 40% of the body’s surface. In March 2020, the FDA approved Pfizer’s supplemental new drug application (sNDA) for Eucrisa (crisaborole) ointment, 2%, extending the lower age limit from 24 months down to 3 months in children with mild-to-moderate AD, also known as eczema. However, it was previously approved by the brand name Eucrisa for use in adults and children 2 years of age and older. This supplemental approval made Eucrisa the first and only steroid-free topical prescription medication for mild-to-moderate AD patients as young as 3 months of age.

Product details in the report…

Dupixent (dupilumab): Regeneron Pharmaceuticals

Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins and is not an immunosuppressant. Data from Dupixent clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in AD, asthma, and chronic rhinosinusitis with nasal polyposis. Dupixent is currently approved in more than 60 countries, and more than 190,000 patients have been treated globally. In May 2020, the US FDA approved Dupixent (dupilumab) for children aged 6–11 years with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. However, the drug is not yet approved for treating AD patients below 6 years of age and is currently in Phase III clinical developmental trial for participants ≥ 6 months to <18 years of age with AD in collaboration with Sanofi and is planning for label expansion in this population. Additionally, the company is also conducting a phase III trial in Japanese pediatric patients with AD.

Product details in the report…

Corectim Ointment: Japan Tobacco and Torii Pharmaceutical

Corectim (delgocitinib) Ointment 0.5% is a non-steroidal topical product and the world’s first topical JAK inhibitor that improves AD by inhibiting the action of all members of the JAK family [JAK1, JAK2, JAK3, and tyrosine kinase 2], which play a key role in immune activation signaling in cells, by suppressing the overactivation of immune responses. In May 2020, the drug completed a Phase II clinical trial for a period of 8 weeks in adult subjects with AD within the US, however, the results of this trial has not been published yet. JT has received manufacturing and marketing approval for Corectim Ointment 0.25% (delgocitinib) for pediatric AD (aged 2 to < 16) in Japan in March 2021. In addition, JT has received approval for additional pediatric dosage and administration for Corectim Ointment 0.5%. Under the terms of the agreement between JT and Torii, Corectim Ointment 0.25% will be sold exclusively by Torii in Japan, following its inclusion in the National Health Insurance (NHI) price list. Separately, the Phase III clinical study in infant patients with atopic dermatitis (aged 6 to < 24 months) for delgocitinib is being conducted in Japan (Torii Pharmaceutical, 2021). Additionally, Leo Pharma is currently conducting a phase I trial of the drug in pediatric subjects (2-17 years) and adult subjects (18 years and above) with moderate to severe AD and had previously completed a phase II dose-ranging study in adult patients with mild to severe AD.

Product details in the report…

Olumiant (baricitinib) ± TCS: Eli Lilly and Company

Baricitinib (LY3009104) – discovered by Incyte and developed under license by Lilly and marketed as Olumiant – is an oral selective Janus kinase (JAK) 1/JAK2 inhibitor. The drug is already approved in EU for the treatment of moderate and severe AD. It is the first medicine for moderate and severe AD that patients can be taken orally. It is also approved in over 40 countries for the treatment of adults with moderate to severe AD who are candidates for systemic therapy. Eli Lilly and partner Incyte have filed a regulatory review for JAK inhibitor Olumiant to treat AD in the US. However, the marketing authorization holder for Olumiant is Eli Lilly Nederland. In July 2021, the US FDA announced that it will not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental new drug application (sNDA) for baricitinib for the treatment of adults with moderate to severe AD. The delay is related to the FDA's ongoing assessment of JAK inhibitors. Additionally, the drug is being evaluated in a phase III trial in children and teenage participants with moderate-to-severe AD.

Product details in the report…

Rinvoq (upadacitinib): AbbVie

Upadacitinib (ABT-494) – discovered and developed by AbbVie scientists and marketed as Rinvoq – is a selective and reversible JAK inhibitor that was approved by FDA and EMA in August 2019 and December 2019, respectively, for adult patients with moderately to severely active rheumatoid arthritis. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. The therapy is currently under review by the FDA. Although the European Commission in August 2021 approved Rinvoq to treat adults and adolescents with AD, the FDA extended the review period as it reviews safety data for this class of therapies. The drug is currently being studied in a Phase III trial as a once-daily oral therapy for moderate-to-severe AD and several other immune-mediated diseases.

Product details in the report…

Cibinqo (abrocitinib): Pfizer

Abrocitinib (PF-04965842) is an oral, small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 modulates multiple cytokines involved in the pathophysiology of AD, including interleukin (IL)-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP). In September 2021, UK’s MHRA granted marketing authorization for Pfizer’s Cibinqo (abrocitinib) for adults and adolescents with moderate to severe AD. In September 2021, Japanese MHLW approved the drug for the treatment of moderate to severe AD in adults and adolescents aged 12 years and older with inadequate response to existing therapies. However, In April 2021, the company announced that the FDA extended the priority review period for the New Drug Application for abrocitinib for the treatment of adults and adolescents with moderate to severe AD. The Prescription Drug User Fee Act goal date was extended three months to Q3 2021.

Product details in the report…

Atopic Dermatitis (AD) Emerging Drugs

B244: AOBiome Therapeutics

AOBiome’s B244 is a patented, proprietary, topical formulation incorporating a single strain of beneficial ammonia-oxidizing bacteria (AOB), Nitrosomonas eutropha D23. B244 is designed to repopulate the skin microbiome with AOBs normally found on the body but frequently stripped away by most soaps. Once deployed on the skin, B244 converts ammonia to nitrite, known to have antibacterial properties, and to nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. The drug is currently undergoing a phase II trial pruritus (itch) caused by AD (eczema) in adults ages 18–65 years in various locations.

Product details in the report…

Ly3650150: Eli Lilly and Company

Lebrikizumab (Ly3650150, Drm06), a novel, investigational, monoclonal antibody, is designed to bind IL-13 with very high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling, thereby inhibiting the biological effects of IL-13 in a targeted and efficient fashion. IL-13 is believed to be a central pathogenic mediator that drives multiple aspects of the pathophysiology underlying the range of signs and symptoms of AD by promoting type II inflammation and mediating its effects on tissue, resulting in skin barrier dysfunction, itch, skin thickening, and infection. The FDA has granted Fast Track designation to lebrikizumab for moderate-to-severe AD in patients aged 12 years and older and 40 kg or greater. The drug is being evaluated in five Phase III studies, ADvocate1 and ADvocate2 monotherapy studies and ADhere study in combination with topical corticosteroids to confirm its safety and efficacy in adolescent and adult patients, ages 12 years and older and 40 kg or greater, with moderate-to-severe AD, along with the ADore adolescent open-label safety study and ADjoin long term extension study. Almirall has licensed the rights to develop and commercialize the novel monoclonal antibody for the treatment of dermatology indications, including AD, in Europe. Meanwhile, Eli Lilly has exclusive rights for the development and commercialization of lebrikizumab in the US and the rest of the world outside Europe.

Product details in the report…

Etrasimod: Arena Pharmaceuticals

Etrasimod (APD334) is a next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator discovered by Arena and designed for optimized pharmacology and engagement of S1P receptor 1, 4, and 5 providing systemic and local effects on specific immune cell types. The drug has the potential to treat multiple immune-mediated inflammatory diseases, including ulcerative colitis, Crohn’s disease, AD, and alopecia areata. In November 2020, based on the compelling profile in the ADVICE trial, the company mentioned that the drug would be proceeding further into a Phase III registration program. In July 2021, the company evaluated an updated open-label extension data set from the Phase II ADVISE trial for 2 mg etrasimod in AD which demonstrated meaningful effects at week 16 of the OLE period on validated Investigator Global Assessment at 47%, EASI-75 at 72%, and Peak Pruritis Numeric Rating Scale at 61% with consistent safety profile out to one year.

Product details in the report…

FB825: Oneness Biotech

FB825 is a humanized monoclonal antibody that binds to the CεmX domain of membrane form IgE, leading to the death of IgE+ B lymphocytes by inducing apoptosis and antibody-dependent cellular cytotoxicity (ADCC). The drug has both therapeutic as well as preventive effects in allergic diseases. In April 2020, LEO Pharma signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan) covering the development and commercialization of the novel AD drug candidate, FB825. Moreover, the company plans to proceed with primary efficacy analysis in Q4 2021. Furthermore, the data readout is anticipated in March 2022 and completion of the clinical study report is expected in Q2 2022.

Product details in the report…

Atopic Dermatitis (AD) Market Outlook

The treatment of AD aims to reduce the duration, severity, and frequency of disease exacerbations (flares). It is implemented in a step-wise manner according to disease severity (mild, moderate, or severe).

Off-label treatment, especially systemic immunosuppressants and systemic (oral and injectable) corticosteroids (SCSs) are frequently prescribed for patients unresponsive to topical therapy. Systemic corticosteroids (SCS) are indicated for short-term treatment of acute severe AD. Although SCS rapidly improves symptoms, they are not recommended for long-term use because of the adverse events.

Optimal AD management includes topical corticosteroids (TCs) as the first-line treatment for AD flare-ups. The potencies of these topical corticosteroids range from the group I, which is most potent (e.g., clobetasol [Temovate]), through group VII, which is least potent (e.g., hydrocortisone 1%). However, TCS has various side-effects and is not recommended for long-term use. The principal complication of prolonged application of topical corticosteroids, especially those of higher-potency, is skin atrophy. Other local complications include telangiectasia, striae, hypopigmentation, and corticosteroid acne.

Topical calcineurin inhibitors, such as pimecrolimus (Elidel) and tacrolimus (Protopic), are immunomodulators and are considered second-line therapy. They are generally reserved for short-term or intermittent long-term therapy in persons with moderate-to-severe AD, especially when there is concern that the ongoing use of topical corticosteroids is causing adverse effects, such as atrophy.

Two topical calcineurin inhibitors (TCIs), pimecrolimus 1% cream (Elidel) and tacrolimus 0.03% ointment (Protopic), which selectively inhibit the synthesis of inflammatory cytokines released from T-cells and mast cells, have been available as second-line therapy since 2000–2001, for the short-term and non-continuous chronic treatment of mild-to-moderate AD in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.

Besides the above-mentioned off-label therapies, the treatment regimen of AD also involves certain approved and marketed therapies. Pfizer’s Eucrisa/Staquis (crisaborole, 2%) is a non-steroidal, phosphodiesterase-4 (PDE4) inhibitor that is approved for the topical treatment of mild-to-moderate AD in patients 2 years of age and older. It was approved in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan in December 2016, with a label expansion in March 2020, extending the lower age limit from 24 months down to 3 months in children, which makes it the only medication for such young population.

Additionally, Dupixent (dupilumab), which is considered a blockbuster drug, is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins and is not an immunosuppressant. It is being jointly developed by Regeneron and Sanofi and is FDA approved for the treatment of asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP), along with AD.

Another therapy, Corectim (delgocitinib) Ointment 0.5%, is a nonsteroidal topical product and the world’s first topical JAK inhibitor that improves AD by inhibiting the action of all members of the JAK family. It is currently only approved in Japan for AD; however, Leo Pharma has licensed the drugs from Japan Tobacco (JT) to develop and commercialize the drug in the US and EU markets.

In September 2020, Olumiant (baricitinib), an oral selective JAK 1/JAK2 inhibitor, received approval in the European Union to treat adult patients with moderate-to-severe AD who are candidates for systemic therapy. It is the first oral JAK inhibitor to treat moderate-to-severe AD in adult patients who are candidates for systemic therapy in the EU and offers a different mode of action to the currently available treatment options. It is not yet approved by the FDA due to a black box warning associated with KAK inhibitors. However, it is approved to treat rheumatoid arthritis (RA) in the US and over 60 countries. Additionally, Eli Lilly and partner Incyte have filed a regulatory review for Olumiant to treat AD in the US.

Recently, the European Commission in August 2021 approved Rinvoq to treat adults and adolescents with AD. Discovered and developed by AbbVie, the drug is a selective and reversible JAK inhibitor. The US FDA extended the review period for the drug’s approval to review safety data for JAK inhibitors after Pfizer released a postmarketing study of a cardiovascular safety trial of its JAK inhibitor Xeljanz (tofacitinib).

Another recently approved drug, Opzelura (ruxolitinib) cream, is a potent, selective inhibitor of JAK1 and JAK2 that, when applied topically, provides the opportunity to directly target diverse pathogenic pathways that underlie AD. In September 2021, Incyte announced that the US FDA had approved Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild-to-moderate AD in non-immunocompromised patients aged ≥12 whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Opzelura is the first and only topical formulation of a JAK inhibitor approved in the United States

Cibinqo (abrocitinib) is an oral, small molecule, Janus kinase (JAK) 1 inhibitor developed by Pfizer for AD in the pediatric and adult population. The US FDA granted Priority Review designation to the company’s NDA for Abrocitinib (100mg and 200mg); however, the decision is pending owing to the safety concerns associated with JAK inhibitors. In September 2021, UK’s MHRA granted marketing authorization for abrocitinib for adults and adolescents with moderate-to-severe AD. In September 2021, Japanese MHLW also approved the drug to treat moderate-to-severe AD in adults and adolescents aged ≥12 with inadequate response to existing therapies.

Adtralza (tralokinumab) specifically neutralizes the IL-13 cytokine, a key driver of the underlying inflammation in AD. According to the trial results in the adult population, tralokinumab 300 mg combined with TCS as needed was effective and well-tolerated in patients with moderate‐to‐severe AD. Tralokinumab monotherapy was superior to placebo at 16 weeks of treatment and was well tolerated up to 52 weeks of treatment. LEO Pharma has already completed multiple Phase III trials and is still conducting another Phase III trial. In June 2021, Adtralza was approved by the European Commission for adults with moderate-to-severe AD in Europe and by the Medicines and Healthcare products Regulatory Agency in Great Britain. Additional regulatory filings are underway with other health authorities worldwide. The company has completed multiple Phase III trials and is still conducting another Phase III trial to treat moderate-to-severe AD in adults.

The developing pipeline of AD holds budding key players such as lebrikizumab (Eli Lily), nemolizumab/CD14152 (Galderma), difamilast (Otsuka Pharmaceuticals), and roflumilast (Arcutis Biotherapeutics). These emerging drugs, predicted to be launched during the forecast period, are likely to change the current market dynamics of AD treatment, thereby boosting the current market size of AD. Following the late-stage products, a wide array of mid-stage or Phase II promising interventions are expected to be launched soon in the market, including B244 (AOBiome Therapeutics), etrasimod/APD334 (Arena Pharmaceuticals), FB825 (Oneness Biotech), DS107 (DS Biopharma), bermekimab (Janssen), KY1005 (Sanofi/Kymab), and Q301 (Zileuton) (Qurient).

Key Findings

This section provides the total Atopic Dermatitis (AD) market size and market size by therapies in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

  • The market size of AD in the 7MM is estimated to be USD 14,172 Million in 2020.
  • Currently, the treatment regimen of AD in the US involves the use of Topical treatment options such as emollients, topical corticosteroids (TCS) Topical calcineurin inhibitors (TCIs) and systemic treatment such as immunosuppressant, corticosteroids, Dupixent, Eucrisa (Crisaborole) 2% ointment, Corectim Ointment and others (phototherapy).
  • Expected Launch of potential therapies such as B244, Lebrikizumab (LY3650150), Etrasimod (APD334), Abrocitinib/PF-04965842, FB825, Nemolizumab (CD14152), Difamilast, DS107, Bermekimab, KY1005, ARQ-151/ Roflumilast cream, and others may increase the market size in coming years.
  • Throughout the study period, the United States accounts for the largest market size of AD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. The US market accounted for USD 9,389 Million in 2020.
  • Among the EU5 countries, the UK had the highest market size with USD 851 Million in 2020, while Spain had the lowest market size of AD with USD 560 Million in 2020 during the study period 2018–2030.
  • The Japanese AD market was USD 1,141 Million in 2020.

Atopic Dermatitis (AD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Atopic Dermatitis (AD) market or expected to get launched in the market during the study period 2018–2030. The analysis covers Atopic Dermatitis (AD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Atopic Dermatitis (AD) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Atopic Dermatitis (AD) emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Atopic Dermatitis (AD) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Atopic Dermatitis (AD), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Atopic Dermatitis (AD) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Atopic Dermatitis (AD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Atopic Dermatitis (AD) market; historical and forecasted is included in the report, covering the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan Atopic Dermatitis (AD) market.

Report Highlights

  • In the coming years, Atopic Dermatitis (AD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis (AD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Delvelnsight has analysed the total prevalent and total diagnosed prevalent population of Atopic Dermatitis (AD).
  • Delvelnsight has analysed gender-specific distribution of AD. As per the analysis, AD is more prevalent in females than in males.
  • In addition, severity-specific data of AD in children and adults was analyzed, according to which the population of AD can be categorized as mild, moderate and severe AD. As per the DelveInsight estimates, it has been found that the mild form of AD included maximum cases, while minimum number of cases were found in severe form of AD in both populations. This trend is clearly evident in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan for the study period 2018–2030.

Analyst Comments

  • With the emerging key players in the market, it is quite confirmed that the treatment for AD will evolve in the upcoming years while giving AD patients a new ray of hope.
  • Based on the analysis, it is evident that the current market is dominated by the use of Dupixent as the first-line pharmacological treatment of the condition in both adults and adolescents. Moreover, the company is conducting clinical trials to evaluate the safety and efficacy of the drug for pediatric patients. Dupixent was approved by the US FDA for children aged 6 to 11 years with moderate-to-severe AD. We are quite buoyant with respect to the efficacy of the drug for patients 6 months to 5 years of age. If approved, the drug will capture a major market share for all age groups.
  • The emerging pipeline for the treatment of adult patients with AD is quite extensive. Among the upcoming therapies and recently approved therapies such as Rinvoq, DS107, Abrocitinib, and Lebrikizumab hold the potential to capture a major market during the forecasted period owing to better efficacy, ROA, patient pool. The drugs such as Rinvoq have recently been approved in the EU-5 and Abrocitinib has been approved in UK and Japan. However, both the drugs are facing a challenge for their US approval owing to the safety concerns associated with the use of JAK inhibitors. Although the FDA review period has been extended by 3 months, DelveInsight believes that the drugs may enter the US market by next year.
  • A black box warning allied with the use of JAK inhibitors is a well-known barrier for the approval of these drugs in the US. However, owing to the recent approval of ruxolitinib (Opzelura; Incyte), a topical selective JAK1/JAK2 inhibitor, for the treatment of mild to moderate AD in non-immunocompromised patients 12 years and older, we believe that the other JAK inhibitors may be approved during the forecasted period provided they demonstrate better efficacy during their clinical development.
  • In Japan, the only available JAK inhibitors are Corectim and Cibinoq, which might compete with each other in the Japanese AD market. Other JAK inhibitors are also in development and are expected to be approved during the forecast period 2021─2030.
  • The emerging pipeline for the pediatric population with AD holds potential key players such as Dupixent, Abrocitinib, Difamilast, and roflumilast cream. We believe that the drugs may enter the 7MM market soon. Approval of these drugs may provide ray of hope for patients below the age of 6 years suffering from the condition.
  • Additionally, therapies like B244, tradipitant, difelikefalin and others are being developed for the treatment of pruritus in AD, which currently has no approved therapy.

Atopic Dermatitis (AD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Atopic Dermatitis (AD) Pipeline Analysis
  • Atopic Dermatitis (AD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Atopic Dermatitis (AD) Report Key Strengths

  • Ten Years Forecast
  • The United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan Coverage
  • Atopic Dermatitis (AD) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Atopic Dermatitis (AD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Atopic Dermatitis (AD) market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the Atopic Dermatitis (AD) total market size as well as market size by therapies in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan during the forecast period (2021–2030)?
  • What are the key findings pertaining to the market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan?
  • At what CAGR, the Atopic Dermatitis (AD) market is expected to grow at the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan level during the forecast period (2021–2030)?
  • What would be the Atopic Dermatitis (AD) market outlook in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan during the forecast period (2021–2030)?
  • What would be the Atopic Dermatitis (AD) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Atopic Dermatitis (AD)?
  • What is the historical Atopic Dermatitis (AD) patient pool in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan?
  • What would be the forecasted patient pool of Atopic Dermatitis (AD) at the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan level?
  • What will be the growth opportunities in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan with respect to the patient population pertaining to Atopic Dermatitis (AD)?
  • At what CAGR the population is expected to grow in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan during the forecast period (2021–2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Atopic Dermatitis (AD) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Atopic Dermatitis (AD) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan?
  • What are the Atopic Dermatitis (AD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Atopic Dermatitis (AD)?
  • How many therapies are developed by each company for the treatment of Atopic Dermatitis (AD)?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Atopic Dermatitis (AD)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atopic Dermatitis (AD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Atopic Dermatitis (AD) and their status?
  • What are the key designations that have been granted for the emerging therapies for Atopic Dermatitis (AD)?
  • What is the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan historical and forecasted market of Atopic Dermatitis (AD)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Atopic Dermatitis (AD).
  • To understand the future market competition in the AD market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Atopic Dermatitis (AD) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Atopic Dermatitis (AD) market.
  • To understand the future market competition in the Atopic Dermatitis (AD) market.

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. SWOT Analysis

6. Atopic Dermatitis Market Overview at a Glance

6.1. Market Share (%) Distribution by Class of Therapies of Atopic Dermatitis in 2020

6.2. Market Share (%) Distribution by Class ofTherapies of Atopic Dermatitis in 2030

7. Disease Background and Overview

7.1. Signs and Symptoms

7.2. Causes and Triggers

7.3. Clinical presentation

7.4. Pathophysiology

7.5. Skin hypersensitivity – abnormalities of the horny cell layer

7.5.1. Mechanisms involved in inflammation

7.5.2. Pruritus

7.6. Biomarkers

7.6.1. Serum IgE levels

7.6.2. Peripheral eosinophil count

7.6.3. Serum lactate dehydrogenase level

7.6.4. Serum thymus and activation regulated chemokine level

7.7. Characteristics of eruption

7.7.1. Infancy (younger than 2 years)

7.7.2. Childhood/school-age (2–12 years old)

7.7.3. Adolescence/adulthood (13 years and older)

7.8. Differential diagnosis

7.9. Prevention and Management

7.10. Diagnosis

7.11. Diagnostic criteria for eczema

8. Treatment

8.1. Topical treatment

8.1.1. Emollients

8.1.2. Topical Corticosteroids (TCs)

8.1.3. Topical Calcineurin Inhibitors (TCIs)

8.2. Systemic Treatment

8.2.1. Immunosuppressants

8.2.2. Oral Corticosteroids

8.2.3. Interleukin Inhibitors

8.2.4. JAK inhibitors

8.2.5. PDE4 inhibitor

8.2.6. Phototherapy

8.2.7. Antibiotics

8.2.8. Antihistamines

8.2.9. Capsaicin

8.2.10. Systemic Agents for treating pruritus in AD

8.3. Self-care

8.3.1. Bathing Practices

8.3.2. Wet Wrap therapy (WWT)

8.3.3. Stress-Relieving Therapies

9. AD Clinical Guideline: American Academy of Dermatology Association (2014)

9.1. Guidelines for Diagnosis and Assessment

9.1.1. Recommendation for the diagnosis of AD

9.1.2. Recommendations for the use of biomarkers in the assessment of AD

9.1.3. Recommendations for disease severity and clinical outcomes assessment

9.1.4. Recommendations for the assessment of clinical associations of atopic dermatitis

9.2. Guidelines for management and treatment with Topical Therapies

9.2.1. Recommendations for non-pharmacologic interventions for the treatment of AD

9.2.2. Recommendations for use of topical corticosteroids for the treatment of AD

9.2.3. Recommendations for the use of TCIs for the treatment of AD

9.2.4. Recommendations for the use of topical antimicrobials and antiseptics for the treatment of AD

9.2.5. Recommendations for the use of topical antihistamines for the treatment of AD

9.3. Guidelines for Management with phototherapy and systemic agents

9.3.1. Recommendations for the use of phototherapy

9.3.2. Recommendations for the use of systemic immunomodulatory agents

9.3.3. Dosing and monitoring guidelines for the use of selected systemic agents

9.3.4. Recommendations for the use of systemic antimicrobials

9.3.5. Recommendations for the use of systemic antihistamines

9.4. Prevention of disease flares and use of adjunctive therapies and approaches

9.4.1. Recommendation for prevention of flares of AD

9.4.2. Recommendations for educational interventions for AD

9.4.3. Recommendations for testing for coexisting allergic disease

9.4.4. Recommendations for other adjunctive and complementary interventions for the treatment of atopic dermatitis

10. Atopic eczema in under 12s: Diagnosis and management by NICE (updated 2020)

10.1. Assessment of severity, psychological and psychosocial well being, and quality of life

10.1.1. Identification and management of trigger factors

10.2. Treatment

10.2.1. Recommendations for the use of Emollients

10.2.2. Recommendations for the use of Topical corticosteroids

10.2.3. Recommendations for the use of Topical calcineurin inhibitors

10.2.4. Recommendations for the use of Dry bandages and medicated dressings, including wet wrap therapy

10.2.5. Recommendations for the use of of antihistamines

10.2.6. Recommendations for the treatments for infections

10.2.7. Recommendations for the use of of phototherapy and systemic treatments

10.2.8. Recommendations for the use of complementary therapies

10.2.9. Recommendations for education and adherence to therapy

10.2.10 Recommendations of indications for referral

11. Consensus-based European guidelines for the treatment of atopic eczema in adults and children (2018)

11.1. Recommendations for Avoidance and Basic Therapy for AE

11.2. Recommendations for Emollient Therapy

11.3. Recommendations for Dietary Intervention

11.4. Recommendations for Topical anti‐inflammatory therapy

11.5. Recommendations for Antipruritic therapy

11.6. Recommendations for Antimicrobial therapy

11.7. Recommendations for Systemic anti‐inflammatory treatment

11.8. Recommendations for Biological agents

11.9. Recommendations for Other Systemic Treatment

11.10. Recommendations for Allergen‐specific immunotherapy (ASIT)

11.11. Recommendations for Complementary and alternative medicine in atopic eczema

12. Treatment Algorithm

12.1. Japanese Guidelines for Atopic Dermatitis 2020

12.2. Treatment Algorithm of AD in Early Childhood

13. Epidemiology and Patient Population

13.1. Key Findings

13.2. Epidemiology Methodology

13.3. 7MM Prevalent Population of Atopic dermatitis

13.4. 7MM Diagnosed Prevalent Population of Atopic dermatitis

13.5. Assumption and Rationale

13.5.1. United States

13.5.2. EU5

13.5.3. Japan

13.6. The United States

13.6.1. Diagnosed Prevalent Population of Atopic Dermatitis in the United States

13.6.2. Severity-specific distribution of Atopic Dermatitis in Adults in the United States

13.6.3. Severity-specific distribution of AD in Pediatric Population in the United States

13.6.4. Gender-specific Prevalence of Atopic Dermatitis in adults in the United States

13.6.5. Chronic Pruritus Prevalence in Atopic Dermatitis in Adults in the United States

13.7. EU5

13.7.1. Diagnosed Prevalent Population of Atopic Dermatitis in EU5

13.7.2. Severity-specific distribution of Atopic Dermatitis in Adults in EU5

13.7.3. Severity-specific distribution of Atopic Dermatitis in Pediatric Population in EU5

13.7.4. Gender-specific Cases of Atopic Dermatitis (AD) in EU5

13.7.5. Chronic Pruritus Prevalence in Atopic Dermatitis in Adults in EU5

13.8. Japan

13.8.1. Diagnosed Prevalent Population of Atopic Dermatitis in Japan

13.8.2. Severity-specific distribution of Atopic Dermatitis in Adults in Japan

13.8.3. Severity-specific distribution of Atopic Dermatitis in Pediatric Population in Japan

13.8.4. Gender-specific Prevalence of Atopic Dermatitis in adults in Japan

13.8.5. Chronic Pruritus Prevalence in Atopic Dermatitis in adults in Japan

14. Organizations contributing towards AD

15. Patient Journey

16. Marketed Drugs

16.1. Key Competitors

16.2. Dupixent (dupilumab): Sanofi/Regeneron Pharmaceuticals

16.2.1. Product Description

16.2.2. Current Pipeline Activity

16.2.3. Safety and Efficacy

16.3. Eucrisa (crisaborole): Pfizer

16.3.1. Product Description

16.3.2. Safety and Efficacy

16.4. Corectim Ointment: Japan Tobacco and Torii Pharmaceutical

16.4.1. Product Description

16.4.2. Current Pipeline Activity

16.4.3. Safety and Efficacy

16.5. Olumiant (baricitinib) ± TCS: Eli Lilly and Company

16.5.1. Product Description

16.5.2. Current Pipeline Activity

16.5.3. Safety and Efficacy

16.6. Rinvoq (upadacitinib): AbbVie

16.6.1. Product Description

16.6.2. Clinical Development

16.6.3. Safety and Efficacy

16.7. Cibinqo (abrocitinib): Pfizer

16.7.1. Product Description

16.7.2. Clinical Development

16.7.3. Safety and Efficacy

16.8. Adtralza (tralokinumab): LEO Pharma

16.8.1. Product Description

16.8.2. Current Pipeline Activity

16.8.3. Safety and Efficacy

16.9. Opzelura (Ruxolitinib): Incyte Corporation

16.9.1. Product Description

16.9.2. Clinical Development

16.9.3. Safety and Efficacy

17. Emerging Drugs

17.1. Key Competitors

17.2. Ly3650150: Eli Lilly and Company

17.2.1. Product Description

17.2.2. Clinical Development

17.2.3. Safety and Efficacy

17.3. Etrasimod: Arena Pharmaceuticals

17.3.1. Product Description

17.3.2. Clinical Development

17.3.3. Safety and Efficacy

17.4. FB825: Oneness Biotech

17.4.1. Product Description

17.4.2. Clinical Development

17.4.3. Safety and Efficacy

17.5. Nemolizumab: Galderma

17.5.1. Product Description

17.5.2. Clinical Development

17.5.3. Safety and Efficacy

17.6. Difamilast: Otsuka Pharmaceutical

17.6.1. Product Description

17.6.2. Clinical Development

17.6.3. Safety and Efficacy

17.7. DS107: DS Biopharma

17.7.1. Product Description

17.7.2. Clinical Development

17.7.3. Safety and Efficacy

17.8. Bermekimab: Janssen

17.8.1. Product Description

17.8.2. Clinical Development

17.8.3. Safety and Efficacy

17.9. B244: AOBiome Therapeutics

17.9.1. Product Description

17.9.2. Clinical Development

17.9.3. Safety and Efficacy

17.10. KY1005 (Amlitelimab): Sanofi/Kymab

17.10.1. Product Description

17.10.2. Clinical Development

17.10.3. Safety and Efficacy

17.11. Q301: Qurient

17.11.1. Product Description

17.11.2. Clinical Development

17.11.3. Safety and Efficacy

17.12. Roflumilast: Arcutis Biotherapeutics

17.12.1. Product Description

17.12.2. Clinical Development

17.12.3. Safety and Efficacy

17.13. Difelikefalin (Korsuva): Cara Therapeutics

17.13.1. Product Description

17.13.2. Clinical Development

17.13.3. Safety and Efficacy

17.14. Tradipitant: Vanda Pharmaceuticals

17.14.1. Product Description

17.14.2. Clinical Development

17.14.3. Safety and Efficacy

18. Potential of Current Therapies and Emerging Therapies

19. Atopic Dermatitis: Seven Major Market Analysis

19.1. Key Findings

19.2. Market Methodology

19.3. Market Size of Atopic Dermatitis in the 7MM

19.4. Market Outlook

19.5. Attribute Analysis

19.6. Key Market Forecast Assumptions

19.7. United States Market Size

19.7.1. Total Market size of AD

19.7.2. Market Size of Atopic Dermatitis by Current Therapies

19.7.3. Market Size of Atopic Dermatitis by Emerging Therapies

19.8. EU-5 Market Size

19.8.1. Total Market size of AD

19.8.2. Market Size of Atopic Dermatitis by Current Therapies

19.8.3. Market Size of Atopic Dermatitis by Emerging Therapies

19.9. Japan Market Size

19.9.1. Total Market size of AD

19.9.2. Market Size of Atopic Dermatitis by Current Therapies

19.9.3. Market Size of Atopic Dermatitis by Emerging Therapies

20. Market Drivers

21. Market Barriers

22. Unmet Needs

23. KOL Views

24. Market Access and Reimbursement

24.1. United States

24.2. Germany

24.3. United Kingdom

24.4. France

24.5. Italy

24.6. Spain

24.7. Japan

25. Appendix

25.1. Bibliography

25.2. Report Methodology

26. DelveInsight Capabilities

27. Disclaimer

28. About DelveInsight

List of Tables:

  • Table 1: Summary of Atopic Dermatitis Market and Epidemiology (2018–2030)
  • Table 2: Key Events
  • Table 3: Characteristic features of Atopic Dermatitis by age
  • Table 4: Diagnostic features for eczema
  • Table 5: Hanifin and Rajka Criteria for Atopic Dermatitis
  • Table 6: UK working party diagnostic criteria for eczema
  • Table 7: Topical Corticosteroids Ranked by Potency (from Most Potent to Least Potent)
  • Table 8: Features to be considered in the diagnosis of patients with AD
  • Table 9: Dosing and monitoring guidelines for the useof selected systemic agents
  • Table 10: Stepped treatment options
  • Table 11: Treatment recommendation for adults and children with atopic eczema
  • Table 12: Systemic drugs for the treatment of severe atopic eczema
  • Table 13: Treatment recommendation for adults and children with atopic eczema.
  • Table 14: Total Prevalent Population of Atopic dermatitis in the 7MM (2018–2030)
  • Table 15: Diagnosed Prevalent Population of Atopic dermatitis in the 7MM (2018–2030)
  • Table 16: Diagnosed Prevalent Population of AD in the US (2018–2030)
  • Table 17: Severity-specific distribution of Atopic Dermatitis in Adults in the US (2018–2030)
  • Table 18: Severity-specific distribution of AD in Pediatric Population in the US (2018–2030)
  • Table 19: Gender-specific Prevalence of Atopic Dermatitis in adults in the US (2018–2030)
  • Table 20: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in the US (2018–2030)
  • Table 21: Total Prevalent Population of AD in EU5 (2018–2030)
  • Table 22: Total Diagnosed Prevalent Population of AD in EU5 (2018–2030)
  • Table 23: Severity-specific Cases of AD in EU5 (2018–2030)
  • Table 24: Severity-specific Cases of AD in Pediatric Population EU5 (2018–2030)
  • Table 25: Gender-specific Cases of AD in EU5 (2018–2030)
  • Table 26: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in EU5 (2018–2030)
  • Table 27: Prevalent Population of Atopic Dermatitis in Japan (2018–2030)
  • Table 28: Diagnosed Prevalent Population of AD in Japan (2018–2030)
  • Table 29: Severity-specific distribution of Atopic Dermatitis in Adults in Japan (2018–2030)
  • Table 30: Severity-specific distribution of AD in Pediatric Population in Japan (2018–2030)
  • Table 31: Gender-specific Prevalence of Atopic Dermatitis in adults in Japan (2018–2030)
  • Table 32: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in Japan (2018–2030)
  • Table 33: Organizations contributing toward AD
  • Table 34: Comparison of Marketed drugs
  • Table 35: Dupixent (dupilumab), Clinical Trial Description, 2021
  • Table 36: Delgocitinib, Clinical Trial Description, 2021
  • Table 37: Baricitinib, Clinical Trial Description, 2021
  • Table 38: Upadacitinib, Clinical Trial Description, 2021
  • Table 39: PF-04965842, Clinical Trial Description, 2021
  • Table 40: Tralokinumab, Clinical Trial Description, 2021
  • Table 41: Ruxolitinib, Clinical Trial Description, 2021
  • Table 42: Comparison of emerging drugs under development
  • Table 43: Comparison of emerging drugs under development for pruritus in AD
  • Table 44: Ly3650150, Clinical Trial Description, 2021
  • Table 45: Etrasimod, Clinical Trial Description, 2021
  • Table 46: FB825, Clinical Trial Description, 2021
  • Table 47: Nemolizumab, Clinical Trial Description, 2021
  • Table 48: Difamilast, Clinical Trial Description, 2021
  • Table 49: DS107, Clinical Trial Description, 2021
  • Table 50: Bermekimab, Clinical Trial Description, 2021
  • Table 51: B244, Clinical Trial Description, 2021
  • Table 52: KY1005, Clinical Trial Description, 2021
  • Table 53: Q301, Clinical Trial Description, 2021
  • Table 54: Roflumilast, Clinical Trial Description, 2021
  • Table 55: Difelikefalin, Clinical Trial Description, 2021
  • Table 56: Tradipitant, Clinical Trial Description, 2021
  • Table 57: 7 Major Market Size of Atopic Dermatitis, in USD Million (2018–2030)
  • Table 58: Attribute analysis (Pediatric patient pool)
  • Table 59: Attribute analysis (Adult patient pool)
  • Table 60: Attribute analysis (Pruritus in AD patient pool)
  • Table 61: Key Market Forecast Assumptions for Rinvoq
  • Table 62: Key Market Forecast Assumptions for Cibinqo
  • Table 63: Key Market Forecast Assumptions for OPZELURA
  • Table 64: Key Market Forecast Assumptions for Adtralza
  • Table 65: Key Market Forecast Assumptions for Olumiant
  • Table 66: Key Market Forecast Assumptions for Lebrikizumab
  • Table 67: Key Market Forecast Assumptions for Etrasimod
  • Table 68: Key Market Forecast Assumptions for Nemolizumab
  • Table 69: Key Market Forecast Assumptions for Defamilast
  • Table 70: Key Market Forecast Assumptions for FB825
  • Table 71: Key Market Forecast Assumptions for KY1005
  • Table 72: Key Market Forecast Assumptions for Roflumilast
  • Table 73: Key Market Forecast Assumptions for Difelikefalin
  • Table 74: Key Market Forecast Assumptions for Tradipitant
  • Table 75: Key Market Forecast Assumptions for B244
  • Table 76: Key Market Forecast Assumptions for DS107
  • Table 77: Key Market Forecast Assumptions for Bermekimab
  • Table 78: United States Market Size of AD, USD Million (2018–2030)
  • Table 79: Market size of AD by Current therapies in the US, in USD Million (2018–2030)
  • Table 80: Market size of AD in Adult Population (>18 years) by emerging therapies in the US, in USD Million (2018–2030)
  • Table 81: Market size of AD in pediatric population (<18 years) by emerging therapies in the US, in USD Million (2018–2030)
  • Table 82: EU5 Market Size of AD in USD Million (2018–2030)
  • Table 83: EU5 Market Size of AD by Emerging Therapies in USD Million (2018–2030)
  • Table 84: Market size of AD in Adult Population (>18 years) by emerging therapies in the EU5, in USD Million (2018–2030)
  • Table 85: Market size of AD in pediatric population (<18 years) by emerging therapies in the EU5, in USD Million (2018–2030)
  • Table 86: Japan Market Size of AD, USD Million (2018–2030)
  • Table 87: Market size of AD by Current therapies in Japan in USD Million (2018–2030)
  • Table 88: Market size of AD in Adult Population (>18 years) by emerging therapies in Japan, in USD Million (2018–2030)
  • Table 89: Market size of AD in pediatric population (<18 years) by emerging therapies in Japan, in USD Million (2018–2030)

List of Figures:

  • Figure 1: Algorithm for the management of AD
  • Figure 2: Medical algorithm for the therapeutic management of AD in early childhood, based on the severity
  • Figure 3: Total Prevalent Population of Atopic dermatitis in the 7MM (2018–2030)
  • Figure 4: Diagnosed Prevalent Population of Atopic dermatitis in the 7MM (2018–2030)
  • Figure 5: Diagnosed Prevalent Population of Atopic Dermatitis in the US (2018–2030)
  • Figure 6: Severity-specific distribution of Atopic Dermatitis in Adults in the US (2018–2030)
  • Figure 7: Severity-specific distribution of AD in Pediatric Population in the US (2018–2030)
  • Figure 8: Gender-specific Prevalence of Atopic Dermatitis in adults in the US (2018–2030)
  • Figure 9: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in the US (2018–2030)
  • Figure 10: Total Prevalent Population of AD in EU5 (2018–2030)
  • Figure 11: Total Diagnosed Prevalent Population of AD in EU5 (2018–2030)
  • Figure 12: Severity-specific Cases of AD in Adults in EU5 (2018–2030)
  • Figure 13: Severity-specific Cases of AD in Pediatric Population in EU5 (2018–2030)
  • Figure 14: Gender-specific Cases of AD in EU5 (2018–2030)
  • Figure 15: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in EU5 (2018–2030)
  • Figure 16: Prevalent Population of Atopic Dermatitis in Japan (2018–2030)
  • Figure 17: Diagnosed Prevalent Population of Atopic Dermatitis in Japan (2018–2030)
  • Figure 18: Severity-specific distribution of Atopic Dermatitis in Adults in Japan (2018–2030)
  • Figure 19: Severity-specific distribution of AD in Pediatric Population in Japan (2018–2030)
  • Figure 20: Gender-specific Prevalence of Atopic Dermatitis in adults in Japan (2018–2030)
  • Figure 21: Chronic Pruritus Prevalence in Atopic Dermatitis in adults in Japan (2018–2030)
  • Figure 22: 7 Major Market Size of Atopic Dermatitis, in USD Million (2018–2030)
  • Figure 23: Market Size of Atopic Dermatitis in the United States, USD Million (2018–2030)
  • Figure 24: Market size of AD by Current therapies in the US, in USD Million (2018–2030)
  • Figure 25: Market size of AD by Emerging therapies in the US, in USD Million (2018–2030)
  • Figure 26: Market Size of Atopic Dermatitis in the EU5, USD Million (2018–2030)
  • Figure 27: Market size of AD by Current therapies in the EU5, in USD Million (2018–2030)
  • Figure 28: Market size of AD by Emerging therapies in the EU5, in USD Million (2018–2030)
  • Figure 29: Market Size of Atopic Dermatitis in Japan, USD Million (2018–2030)
  • Figure 30: Market size of AD by Current therapies in Japan, in USD Million (2018–2030)
  • Figure 31: Market size of AD by Emerging therapies in Japan, in USD Million (2018–2030)

List of Companies:

  • Sanofi
    Regeneron Pharmaceuticals
    Pfizer
    Japan Tobacco and Torii Pharmaceutical
    Eli Lilly and Company
    AbbVie
    LEO Pharma
    Incyte Corporation
    Arena Pharmaceuticals
    Oneness Biotech
    Galderma
    Otsuka Pharmaceutical
    DS Biopharma
    Janssen
    AOBiome Therapeutics
    Kymab
    Arcutis Biotherapeutics
    Cara Therapeutics
    Vanda Pharmaceuticals
Atopic Dermatitis (AD) Market

Related Reports

Atopic Dermatitis (AD) - Pipeline Insight, 2023

$ 3000

Atopic Dermatitis (AD) - Pipeline Insight, 2023

Atopic Dermatitis (AD) - Epidemiology Forecast - 2032

$ 4750

Atopic Dermatitis (AD) - Epidemiology Forecast - 2032

Tags:

loader

Request Sample

View Pricing